fda glp-1 compounding crackdown news october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Non-Traditional Channels: The Compounded GLP-1

Pathway activity profiling (papi): from the metabolite profile to the metabolic pathway activity

They are provided for educational purposes only and should not be construed as medical advice or product claims

T cell specific Mfn2 conditional knockout models disrupt these contacts and precipitate metabolic collapse, whereas MFN2 overexpression restored organelle tethering, preserved T cell metabolic fitness, and significantly augments antitumor efficacy, highlighting MAM integrity as a determinant of immunotherapy efficacy (50)

Always discuss any increase with your provider to confirm it's appropriate for your health history, current side effects, and weight-loss goal